Impact of Donor Age and Donor Cytomegalovirus Serostatus on Outcomes After Related Donor Allogeneic Hematopoietic Stem Cell Transplantation
Open Access
- 12 March 2025
- journal article
- Published by Wiley in American Journal of Hematology
- Vol. 100 (6) , 987-997
Abstract
Cytomegalovirus (CMV) infection post‐hematopoietic cell transplantation (HCT) remains a significant cause of morbidity and mortality. While letermovir prophylaxis is available for CMV‐seropositive recipients, optimal donor selection for CMV‐seronegative recipients remains unclear, with donor age often prioritized over CMV serostatus. We investigated the relative impact of donor age and CMV serostatus in CMV‐seronegative recipients (n = 1013) with either CMV‐seropositive (n = 318) or CMV‐seronegative donors (n = 695), who underwent HCT with HLA‐matched sibling donors with calcineurin inhibitor‐based or post‐transplant cyclophosphamide (PTCy)‐based graft‐versus‐host disease prophylaxis, or haploidentical donors with PTCy. Multiple conventional and machine‐learning approaches were employed to account for confounding factors. Across all analyses, CMV‐seropositive donor status was consistently associated with significantly inferior overall survival (OS) and disease‐free survival, primarily driven by increased non‐relapse mortality (NRM). Older donor age showed a statistically significant association with OS and DFS in some but not all models, and its effect size was small (about 1% increased hazard per year in Cox proportional hazard model) compared to the substantial impact of CMV‐seropositive donors (about 27%–33% increased hazards for worse OS, approximately 50%–60% higher NRM in Cox proportional hazard model). However, our machine learning model revealed a more nuanced and complex non‐linear effect of donor age, further demonstrating the adverse impact of donor CMV serostatus. Our findings suggest that prioritizing a CMV‐seronegative donor may be associated with improved outcomes in CMV‐seronegative recipients. Further research is needed to validate these findings and explore underlying mechanisms.Keywords
This publication has 15 references indexed in Scilit:
- Cytomegalovirus Reactivations in Allogeneic Hematopoietic Stem Cell Transplantation from HLA-Matched and Haploidentical Donors with Post-Transplantation CyclophosphamideTransplantation and Cellular Therapy, 2024
- Impact of GVHD prophylaxis on CMV reactivation and disease after HLA-matched peripheral blood stem cell transplantationBlood Advances, 2023
- HLA informs risk predictions after haploidentical stem cell transplantation with posttransplantation cyclophosphamideBlood, 2022
- Risk Factors for Early Cytomegalovirus Reactivation and Impact of Early Cytomegalovirus Reactivation on Clinical Outcomes after T Cell-Replete Haploidentical Transplantation with Post-Transplantation CyclophosphamideTransplantation and Cellular Therapy, 2022
- CMV exposure drives long-term CD57+ CD4 memory T-cell inflation following allogeneic stem cell transplantBlood, 2021
- Optimal Donor Selection for Hematopoietic Cell Transplantation Using Bayesian Machine LearningJCO Clinical Cancer Informatics, 2021
- Posttransplant cyclophosphamide is associated with increased cytomegalovirus infection: a CIBMTR analysisBlood, 2021
- Development of an Unrelated Donor Selection Score Predictive of Survival after HCT: Donor Age Matters MostTransplantation and Cellular Therapy, 2018
- Letermovir Prophylaxis for Cytomegalovirus in Hematopoietic-Cell TransplantationNew England Journal of Medicine, 2017
- High Risk of Death Due to Bacterial and Fungal Infection among Cytomegalovirus (CMV)–Seronegative Recipients of Stem Cell Transplants from Seropositive Donors: Evidence for Indirect Effects of Primary CMV InfectionThe Journal of Infectious Diseases, 2002